Mita Manna, MD, FRCPC - CDK4/6 Inhibitors in HR+/HER2- High-Risk Early Breast Cancer: Considerations in Care

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Science

Share Mita Manna, MD, FRCPC - CDK4/6 Inhibitors in HR+/HER2- High-Risk Early Breast Cancer: Considerations in Care

Sign up to save your podcasts

Mita Manna, MD, FRCPC - CDK4/6 Inhibitors in HR+/HER2- High-Risk Early Breast Cancer: Considerations in Care

Mita Manna, MD, FRCPC - CDK4/6 Inhibitors in HR+/HER2- High-Risk Early Breast Cancer: Considerations in Care

More shows like PeerVoice Oncology & Haematology Video

PeerVoice Brain Behaviour Audio

PeerVoice Oncology & Haematology Audio

PeerVoice Endocrinology & Metabolic Disorders Audio

PeerVoice Digestive Diseases Audio

PeerVoice Digestive Diseases Video

PeerVoice Immunology & Infectious Disease Video

PeerVoice Immunology & Infectious Disease Audio

PeerVoice Internal Medicine Audio

PeerVoice Internal Medicine Video